Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Multiple Myeloma × mirdametinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

daratumumab 2 Dexamethasone 2 vactosertib 1 selinexor 1 pomalidomide 1 mirdametinib 1 fludarabine phosphate 1 carfilzomib 1 aldesleukin 1 Specimen Handling 1 Sirolimus 1 Melphalan 1 Lenalidomide 1 Interleukin-2 1 IL32 protein, human 1 Cyclophosphamide 1 Calcium Dobesilate 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06876142 2026-04-17

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡